Acelyrin, Inc. (NASDAQ:SLRN – Get Rating) shares gapped up prior to trading on Tuesday . The stock had previously closed at $19.27, but opened at $20.00. Acelyrin shares last traded at $19.14, with a volume of 148,015 shares changing hands.
Analysts Set New Price Targets
A number of equities analysts have issued reports on SLRN shares. TD Cowen initiated coverage on Acelyrin in a research report on Tuesday. They issued an “outperform” rating on the stock. Morgan Stanley initiated coverage on Acelyrin in a research report on Tuesday. They set an “overweight” rating on the stock. Jefferies Financial Group initiated coverage on Acelyrin in a research report on Tuesday. They set a “buy” rating and a $31.00 price target on the stock. Finally, Piper Sandler initiated coverage on Acelyrin in a research report on Tuesday. They set an “overweight” rating and a $68.00 price target on the stock.
Acelyrin Stock Performance
Insider Buying and Selling
In related news, CFO Mardi Dier acquired 5,556 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $100,008.00. Following the purchase, the chief financial officer now directly owns 5,556 shares in the company, valued at $100,008. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Beth C. Seidenberg acquired 60,000 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,080,000.00. Following the purchase, the director now directly owns 60,000 shares in the company, valued at $1,080,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mardi Dier purchased 5,556 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The stock was acquired at an average cost of $18.00 per share, with a total value of $100,008.00. Following the purchase, the chief financial officer now owns 5,556 shares of the company’s stock, valued at approximately $100,008. The disclosure for this purchase can be found here. Insiders purchased a total of 1,316,556 shares of company stock worth $23,698,008 in the last three months.
Acelyrin Company Profile
Acelyrin Inc is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep. Acelyrin Inc is based in Agoura Hills, California.
Further Reading
- Get a free copy of the StockNews.com research report on Acelyrin (SLRN)
- A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
- Don’t Worry; Sportsman’s Warehouse Will Get Cheaper
- Trinseo’s Dip, Has Something Changed Or Is It Just A Down Cycle
- The Most Upgraded Stocks From The Q1 Earnings Season
- What U-Haul Earnings Are Showing, Heading Up?
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.
